Solriamfetol (Sunosi) approved by EU as a treatment for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnoea.

Following provisional approval in November the EU has formally approved this medicine for use in Europe. Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) and the condition is thought to affect about 25 patients per 100,000 population.